Vincerx Pharma, Inc.
VINC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $915 | $939 | $340 |
| Gross Profit | $0 | -$915 | -$939 | -$340 |
| % Margin | – | – | – | – |
| R&D Expenses | $15,486 | $28,058 | $52,152 | $40,081 |
| G&A Expenses | $15,977 | $13,636 | $18,953 | $22,575 |
| SG&A Expenses | $15,977 | $13,636 | $18,953 | $22,575 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $31,463 | $41,694 | $71,105 | $62,656 |
| Operating Income | -$31,463 | -$42,609 | -$68,722 | -$62,656 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,389 | $2,452 | $5,738 | $23,350 |
| Pre-Tax Income | -$30,074 | -$40,157 | -$62,984 | -$39,306 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$30,074 | -$40,157 | -$65,367 | -$39,306 |
| % Margin | – | – | – | – |
| EPS | -5.75 | -6.84 | -10.86 | -8.3 |
| % Growth | 15.9% | 37% | -30.8% | – |
| EPS Diluted | -5.75 | -6.84 | -10.86 | -8.3 |
| Weighted Avg Shares Out | 5,234 | 5,873 | 5,799 | 4,737 |
| Weighted Avg Shares Out Dil | 5,234 | 5,873 | 5,799 | 4,737 |
| Supplemental Information | – | – | – | – |
| Interest Income | $472 | $1,251 | $664 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $915 | $939 | $340 |
| EBITDA | -$31,463 | -$39,242 | -$62,045 | -$38,966 |
| % Margin | – | – | – | – |